Early detection of thrombin activity in neuroinflammatory disease

Annals of Neurology

Volumn 75, Issue 2, 2014, Pages 303-308

  Davalos, Dimitrios ^a   Baeten, Kim M ^a   Whitney, Michael A ^b   Mullins, Eric S ^c   Friedman, Beth ^b   Olson, Emilia S ^b   Ryu, Jae Kyu ^a   Smirnoff, Dimitri S ^a   Petersen, Mark A ^a,d   Bedard, Catherine ^a   Degen, Jay L ^c   Tsien, Roger Y ^b,e   Akassoglou, Katerina ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b San Diego   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTHROMBIN; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AXONAL INJURY; CONTROLLED STUDY; DEMYELINATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FIBRIN DEPOSITION; MICROGLIA; MOLECULAR PROBE; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AXONS; BLOOD COAGULATION FACTORS; CONNEXINS; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FIBRIN; GREEN FLUORESCENT PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELIN BASIC PROTEIN; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE FRAGMENTS; POLY I-C; THROMBIN;

EID: 84896543862     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24078     Document Type: Article

References (25)

1. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990; 113: 1477-1489.
2. Kwon EE, Prineas JW,. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol 1994; 53: 625-636.
3. Marik C, Felts PA, Bauer J, et al. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 2007; 130: 2800-2815.
4. Zlokovic BV,. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
5. Adams RA, Bauer J, Flick MJ, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007; 204: 571-582.
6. Davalos D, Ryu JK, Merlini M, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 2012; 3: 1227.
7. Gay D, Esiri M,. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 1991; 114: 557-572.
8. Adams RA, Schachtrup C, Davalos D, et al. Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: lessons from multiple sclerosis. Curr Med Chem 2007; 14: 2925-2936.
9. Davalos D, Akassoglou K,. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012; 34: 43-62.
10. Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076-1081.
11. Inoue A, Koh CS, Shimada K, et al. Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats. J Neuroimmunol 1996; 71: 131-137.
12. Brass LF,. Thrombin and platelet activation. Chest 2003; 124: 18S-25S.
13. Langer HF, Choi EY, Zhou H, et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 2012; 110: 1202-1210.
14. Jiang T, Olson ES, Nguyen QT, et al. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004; 101: 17867-17872.
15. Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) 2009; 1: 382-393.
16. Whitney M, Crisp JL, Olson ES, et al. Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides. J Biol Chem 2010; 285: 22532-22541.
17. Olson ES, Jiang T, Aguilera TA, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 2010; 107: 4311-4316.
18. Chen B, Friedman B, Whitney MA, et al. Thrombin activity associated with neuronal damage during acute focal ischemia. J Neurosci 2012; 32: 7622-7631.
19. Olson ES, Whitney MA, Friedman B, et al. In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integr Biol (Camb) 2012; 4: 595-605.
20. Whitney M, Savariar EN, Friedman B, et al. Ratiometric activatable cell-penetrating peptides provide rapid in vivo readout of thrombin activation. Angew Chem Int Ed Engl 2013; 52: 325-330.
21. Mullins ES, Kombrinck KW, Talmage KE, et al. Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Blood 2009; 113: 696-704.
22. Arai T, Miklossy J, Klegeris A, et al. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol 2006; 65: 19-25.
23. Nguyen QT, Olson ES, Aguilera TA, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A 2010; 107: 4317-4322.
24. Hauser SL, Chan JR, Oksenberg JR,. Multiple sclerosis: prospects and promise. Ann Neurol 2013; 74: 317-327.
25. Merlini M, Davalos D, Akassoglou K,. In vivo imaging of the neurovascular unit in CNS disease. Intravital 2012; 1: 87-94.